Christine Ibilibor

Dr. Christine Ibilibor

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 November 2024 in Cancer Medicine
Verified
Journal Article
Open access
KTKezia Reji Thomas
Kezia Reji Thomas
CJCatherine Joshua
Catherine Joshua
CIChristine Ibilibor
Christine Ibilibor
Objective: Bladder cancer patients experience high levels of disease and treatment‐related distress, however, factors that can mitigate patient‐reported psychological distress are poorly characterized. Thus, this study serves to summarize the burden of psychological distress among bladder cancer patients and identify clinical, psychological, and socioeconomic factors that are associated with varying levels of psychological distress.Methods: We performed a systematic review of studies examining psychological distress in bladder cancer patients. We searched PubMed/MEDLINE, Embase, and PsycINFO from October 2000 to February 2024 according to the PRISMA guidelines. Associations between clinical, psychological, socioeconomic factors, and psychological distress were identified in each study and extracted. The protocol for this review is registered in PROSPERO (CRD42024495568).Results: Using our search strategy, 759 articles were retrieved and 17 met inclusion criteria, representing 2572 bladder cancer patients. Tumor stage (n = 3), younger age (n = 2), female sex (n = 2) the preoperative setting (n = 2), depression/anxiety (n = 2), and negative psychological response to illness (n = 2) were common factors associated with increased psychological distress. Transitioning from the preoperative to the postoperative period (n = 2), postoperative inpatient rehabilitation (n = 2), feeling well informed (n = 2), and social support (n = 2) were associated with decreased psychological distress.Conclusion: While clinical factors associated with increased psychological distress are nonmodifiable, clinical, psychological, and socioeconomic factors associated with decreased psychological distress can be improved upon by healthcare providers to mitigate the distress that bladder cancer patients experience.

2 January 2021 in Arab Journal of Urology
Verified
Journal Article
Open access
CIChristine Ibilibor
Christine Ibilibor
SPSarah P. Psutka
Sarah P. Psutka
JHJesus Herrera
Jesus Herrera
JRJ. Ricardo Rivero
J. Ricardo Rivero
HWHanzhang Wang
Hanzhang Wang
DKDharam Kaushik
Dharam Kaushik
Objective: To compare cancer-specific mortality (CSM) and all-cause mortality (ACM) between patients with and without sarcopenia who underwent radical cystectomy for bladder cancer. Materials and methods: We performed a systematic review and meta-analysis of original articles published from October 2010 to March 2019 evaluating the effect of sarcopenia on CSM and ACM. We extracted hazard ratios (HRs) and 95% confidence intervals (CIs) for CSM and ACM from the included studies. Heterogeneity amongst studies was measured using the Q-statistic and the I 2 index. Meta-analysis was performed using a random-effects model if heterogeneity was high and fixed-effects models if heterogeneity was low. Results: We identified 145 publications, of which five were included in the meta-analysis. These five studies represented 1447 patients of which 453 were classified as sarcopenic and 534 were non-sarcopenic. CSM and ACM were increased in sarcopenic vs non-sarcopenic patients (HR 1.64, 95% CI 1.30–2.08, P < 0.01 and HR 1.41, 95% CI 1.22–1.62, P < 0.01, respectively). Conclusions: Sarcopenia is significantly associated with increased CSM and ACM in bladder cancer. Identifying patients with sarcopenia will augment preoperative counselling and planning. Further studies are required to evaluate targeted interventions in patients with sarcopenia to improve clinical outcomes. Abbreviations: ACM: all-cause mortality; ASA: American Association of Anesthesiologists; BMI: body mass index; CCI: Charlson Comorbidity Index; CSM: cancer-specific mortality; CSS: cancer-specific survival; ECOG: Eastern Cooperative Oncology Group; HR: hazard ratio; NAC: neoadjuvant chemotherapy; NIH: National Institutes of Health; OS: overall survival; RC: radical cystectomy; RCT: randomised controlled trial; SMI: Skeletal Muscle Index

6 January 2022 in Clinical Genitourinary Cancer
Verified
Journal Article
Closed access
CIChristine Ibilibor
Christine Ibilibor
AWAmanda L. Watson
Amanda L. Watson
HWHanzhang Wang
Hanzhang Wang
GGGabriela Gonzalez
Gabriela Gonzalez
SLSitai Liang
Sitai Liang
RRRonald Rodriguez
Ronald Rodriguez

8 May 2025 in Cancers
Verified
Journal Article
Open access
PDF file
AHAaron R Hochberg
Aaron R Hochberg
AHAnnie Huiwen Ho
Annie Huiwen Ho
RTRasheed A.M. Thompson
Rasheed A.M. Thompson
MBMatthew B. Buck
Matthew B. Buck
CLCostas D. Lallas
Costas D. Lallas
MSMihir Shah
Mihir Shah
Prostate cancer (CaP) remains the most diagnosed malignancy in men, and the incidence of high-grade disease at diagnosis is increasing

1 April 2026 in Journal of Urology
Verified
Journal Article
Open access
NZNicole Zeltser
Nicole Zeltser
RHRoni Haas
Roni Haas
CIChristine Ibilibor
Christine Ibilibor
JGJonathan Gelfond
Jonathan Gelfond
MGMartin Goros
Martin Goros
MLMichael A. Liss
Michael A. Liss
Overdiagnosis of prostate cancer (PC) through prostate-specific antigen (PSA) testing at short intervals remains common. While baseline serum PSA abundance < 1 ng/mL warrants infrequent screening, it is critical to foster advanced diagnostic practices for men with baseline serum PSA ≥ 1 ng/mL, who are at higher risk for clinically significant disease. We investigated whether common germline variants could enhance screening recommendations in men with PSA ≥1 ng/mL. Polygenic hazard scores for the risk of PC diagnosis (PHS290) were computed in a diverse, matched, prospective cohort of 310 men with baseline PSA ≥ 1 ng/mL with or without PC. Regression models were used to predict PC clinical risk groups with PHS290, while incorporating clinical covariates and an existing 5-year-risk calculator score. PHS290 stratified individuals with PSA ≥1 ng/mL into risk groups and identified men with intermediate- & high-risk PC. Adding PHS290 to our model for predicting time to intermediate- & high-risk PC improved predictions over an existing pre-biopsy 5-year risk calculator. and Clinical Implications: Our study demonstrates the potential of genetic scores to advance screening guidance. The PC risk stratification capabilities of molecular biomarkers in tiered screening strategies merit further study in large cohorts.

17 January 2024 in medRxiv
Verified
Preprint
Open access
PDF file
CIChristine Ibilibor
Christine Ibilibor
SAShannon Armbruster
Shannon Armbruster
RPRell Parker
Rell Parker
JYJia-Ray Yu
Jia-Ray Yu
ABAndrew Barros
Andrew Barros
The generalizability of data derived from randomized controlled trials is of paramount importance given their utility in the Food & Drug Administration (FDA) drug approval process. An essential part of this process is the inclusion of reliably reported gender, race and ethnicity data in trials that lead to FDA drug approval. Despite previous mandates by the FDA and Clinicaltrials.gov , gender and race-specific data remains under reported. We reviewed 100 most recently approved FDA medications, and abstracted the clinical trial data from Clinicaltrials.gov that supported their approval. We then compared these FDA approved trials to non-FDA approved trials from the same year and of similar size. We found that 40% of the FDA trials were missing race/ethnicity information, while 24% of these trials did not include gender information. We demonstrate that there remains a significant amount of missing gender and racial/ethnic data in trials that lead to FDA-approved medications.